Global Blood Therapeutics buoyed by good news from FDA; Cigna to help cover pricey therapies
→ Global Blood Therapeutics $GBT has much to cheer about. Not only has the FDA granted its sickle cell disease (SCD) drug priority review, the agency is not holding an advisory committee to deliberate on the drug. Shares of the San Francisco-based biotech jumped more than 14% to $54.25 before the bell on Thursday. The US regulator is expected to decide on the once-daily pill voxelotor — which is designed to work by increasing hemoglobin’s affinity for oxygen — by February 26, 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.